) posted 92 cents, vs. $1.47 fourth-quarter earnings per share (including items) on a 59% rise in total operating revenue. The company sees $1.82 first-quarter earnings per share and $7.75 2005 earnings per share on operating revenue of about $45.7 billion. S&P reiterates strong buy and raises its target price.
) records show an external committee monitoring Vioxx's safety in clinical trial had early data suggesting users could be at increased risk of heart problems after just 4 months, according to the Wall Street Journal.
) posted lower-than-expected 44 cents, vs. 41 cents fourth-quarter earnings per share on flat revenue. The company cites tougher a retail environment and disappointing performance in the U.S. Toys segment.
Japanese electronics giants Matsushita (MC
) and Hitachi (HIT
) agree to join forces in the plasma display panel business to stay competitive.
Chinese web portal Sohu.com (SOHU
) posted 17 cents, vs. 28 cents fourth-quarter earnings per share despite a 68% revenue rise. The company sees 14 cents to 16 cents first-quarter earnings per share on revenue of $22.5 million to $23.5 million.
) posted better-than-expected 29 cents, vs. 41 cents fourth-quarter earnings per share despite a 1.8% revenue rise. The health insurer raised its $1.95 2005 earnings per share guidance to about $2.05. The company cites an anticipated positive impact of federal income tax gain contingency.
Aircraft component manufacturer Goodrich (GR
) posted 30 cents, vs. 19 cents fourth-quarter earnings per share on a 12% sales rise.
Piper Jaffray says Blue Nile (NILE
) fourth-quarter results may not sparkle and reiterates market perform. The company is scheduled to post fourth-quarter results Tuesday after the market closes.
The New York Post reports Oshkosh B'Gosh (GOSHA
) interviewed investment banks to help it explore strategic alternatives, including a possible sale, sources familiar with the situation said.
Bear Stearns cuts Synaptics (SYNA
) $53 calendar year-end price target to $49.
Pharmaceutical company Axonyx (AXYX
) says its first Phase III clinical trial with Phenserine, in development for mild to moderate Alzheimer's disease, showed no statistically significant improvement over placebo in primary endpoints.
Syneron Medical (ELOS
) posted 30 cents, vs. 6 cents fourth-quarter earnings per share on a 47% revenue rise. The company raises 2005 revenue guidance to $78 million to $80 million from $75 million. It says 2005 revenue guidance is set at $17 million to $18 million and plans to offer about 8 million shares.
America Service (ASGR
) sees about 43 cents fourth-quarter earnings per share and about 82 cents earnings per share for 2004. The company sees $1.42 to $1.53 2005 earnings per share on revenue of $600 million to $700 million.
) posted flat January same-store sales and 14% higher total revenue.
Owens & Minor (OMI
) raised its quarterly dividend 18%.